跳到正文
ESMO 2026持续更新

NATALEE

51 篇报道2 个报道来源11 小时前更新

先了解这件事

报道摘要

诺华宣布NATALEE三期试验六年随访结果，凯丽隆（瑞波西利）联合内分泌治疗较内分泌单药使高复发风险HR+/HER2-早期乳腺癌患者死亡风险降低19%（HR=0.809，95% CI 0.661-0.989）。

摘自 中文产业新闻

报道时间线

沿着报道，了解事件的不同侧面。

10月24日
  1. ESMO 2026 现场信号
    Oncologists Discuss NATALEE Trial
  2. ESMO 2026 现场信号
    #ESMO26 | Per la rubrica #OncoSTEPS Armando Orlandi commenta l’update a 6 anni dello studio NATALEE.👇
  3. ESMO 2026 现场信号
    Six-year NATALEE data at #ESMO2026: adjuvant ribociclib plus an NSAI reduced the risk of death by 19% vs endocrine therapy alone in HR+/HER2− early breast cancer. Company-reported;
  4. ESMO 2026 现场信号
    🚨 NATALEE: Kisqali® + ET reduced death risk by ~20% in high-risk HR+/HER2− early breast cancer (OS HR 0.809). 6-year iDFS benefit: 5.3%.
  5. ESMO 2026 现场信号
    🤩 @OncBrothers highlighting 🔑 studies presented on Day 1 of #ESMO26
  6. 中文产业新闻
    2026 ESMO NATALEE试验6年OS显示N0至N+Ⅱ–Ⅲ期患者长期生存获益

    NATALEE试验6年OS结果显示，N0至N+的广泛Ⅱ–Ⅲ期患者获得长期生存获益。相关结果于2026 ESMO公布，但材料未提供HR、CI、p值或样本量。

  7. ESMO 2026 现场信号
    📍 Live from #ESMO26 in Madrid!
  8. ESMO 2026 现场信号
    #NATALEE at 6 years: sustained iDFS benefit with adjuvant ribociclib.
  9. ESMO 2026 现场信号
    ESMO 2026’nın ilk gününden seçtiklerimiz Onkoloji Gazetesi’nde.
  10. ESMO 2026 现场信号
    עדכונים נוספים מהכנס:
  11. ESMO 2026 现场信号
    24-hour top trending trials we're tracking at #ESMO26 as we start day 2, based on posts by validated HCPs on social media:
  12. 中文产业新闻精选
    NATALEE六年随访显示凯丽隆联合内分泌治疗使高复发风险HR+/HER2-早期乳腺癌死亡风险降低19%

    诺华宣布NATALEE三期试验六年随访结果，凯丽隆（瑞波西利）联合内分泌治疗较内分泌单药使高复发风险HR+/HER2-早期乳腺癌患者死亡风险降低19%（HR=0.809，95% CI 0.661-0.989）。

  13. ESMO 2026 现场信号
    #ScienceLink #Madrid2026 #ESMO26 #NATALEE #Ribociclib
  14. ESMO 2026 现场信号
    NATALEE: Adjuvant Ribociclib Plus NSAI Improves Long-Term Survival in HR+/HER2- Early Breast Cancer
  15. ESMO 2026 现场信号
    Encouraging 6-year #NATALEE results presented at #ESMO26 ! 🎯
  16. ESMO 2026 现场信号
    Day 1 #ESMO26 highlights
  17. ESMO 2026 现场信号
    Clear, compact NATALEE OS summary from @stolaney1. The detail fellows mix up: NATALEE used ribociclib 400 mg for 3 years and included high-risk node-negative stage II disease, whil
  18. ESMO 2026 现场信号
    🚨 #ESMO26 moves fast your inbox should help you keep up, not add more noise.
10月23日
  1. ESMO 2026 现场信号
    🚨 Day 1 highlights from #ESMO26 are here!
  2. ESMO 2026 现场信号
    🚨 The daily OncoAlert Newsletter is LIVE from Madrid 🇪🇸 #ESMO26
  3. ESMO 2026 现场信号
    #ESMO26 | NATALEE: 6-year outcomes
  4. ESMO 2026 现场信号
    NATALEE 6-y results are out! #ESMO26
  5. ESMO 2026 现场信号
    At 15y analyses, extended ET did not show an OS benefit. Now both adjuvant abema and ribo have positive OS results. Do you think there is still a role for extending ET after adjuva
  6. ESMO 2026 现场信号
    Great news! NATALEE is positive for overall survival. Great presentation from Dr Slamon. Big thanks to all the patients, and research nurses who risked themselves during COVID to
  7. ESMO 2026 现场信号
    NATALEE: 6-Year Update at #ESMO26
  8. ESMO 2026 现场信号
    Cowabunga! 🌊 Riding the Early & Adjuvant Breast Cancer Wave 🏄🏻‍♂️🤙🏻 from #ESMO26
  9. ESMO 2026 现场信号
    @myesmo #ESMO26. The start to an exciting meeting - first two oral BC sessions today. The first session with OS data from Natalee, long term benefit from extended letrozole in B42,
  10. ESMO 2026 现场信号
    #ESMO26
  11. ESMO 2026 现场信号
    Oral abstract #BreastCancer session at #ESMO26: updated data from NATALEE trial simultaneously published in @Annals_Oncology
  12. ESMO 2026 现场信号
    NATALEE 6-year OS analysis shows modest (early…given what we just saw in NSABP42…) improvement in OS.
  13. ESMO 2026 现场信号
    📢 #ESMO26 concomitant paper - Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year fol
  14. ESMO 2026 现场信号
    NATALEE 6-year analysis demonstrated an OS benefit with adjuvant ribociclib in HR+/HER2− early breast cancer (HR 0.81; absolute benefit 2.1%), with sustained iDFS benefit (HR 0.74;
  15. ESMO 2026 现场信号
    術後アジュバントのリボシクリブのNATALEE試験 6年OSデータ。
  16. ESMO 2026 现场信号
    6-year results of Natalee (ribociclib): improvements in OS, BCSS, iDFS, DRFS - some subgroups analyses still required
  17. ESMO 2026 现场信号
    #ESMO26
  18. ESMO 2026 现场信号
    One of the most awaited abstracts of #ESMO26: OS results of the NataLEE trial
  19. ESMO 2026 现场信号
    During the NATALEE readout, it's the top trending trial in the live HCP conversation at #ESMO26.
  20. ESMO 2026 现场信号
    NATALEE: OS data
  21. ESMO 2026 现场信号
    "Not ready to call NATALEE an OS win." @nlindenberg
  22. ESMO 2026 现场信号
    Ad #ESMO26 novità per il trattamento di alcune forme di #tumorealseno dai risultati dell'analisi di follow-up a 6 anni dello studio NATALEE.
  23. ESMO 2026 现场信号
    Studio di Fase III #NATALEE, presentati ad #ESMO26 i risultati dell’analisi di follow-up a 6 anni.
  24. ESMO 2026 现场信号
    Today at #ESMO26, the 6-year results of NATALEE will be presented. Ahead of the presentation, my personal view on the survival gains with adjuvant CDK4/6 inhibitors…
  25. ESMO 2026 现场信号
    NATALEE: We’re talking about saving lives!
  26. ESMO 2026 现场信号
    #ESMO26
  27. ESMO 2026 现场信号
    NATALEE OS: no formal significance; the analysis is descriptive (nominal P, no alpha). monarchE, by contrast, had a prespecified alpha-controlled OS analysis and met it. NATALEE: H
  28. ESMO 2026 现场信号
    #ESMO26 | NATALEE – 6-year results (Pre-presentation abstract)
  29. ESMO 2026 现场信号
    Right now there's growing anticipation among HCPs for @NovartisCancer NATALEE trial 6-year breast cancer survival results due to be presented at #ESMO26, according to @CREATION Int…
  30. ESMO 2026 现场信号
    #ESMO26 tomorrow the 6-y survival results of the NATALEE trial will be presented in Madrid, 2:25 pm

本事件热度走势

当前热度 177·可比范围峰值 237（10月25日 01:00）·近 24 小时可比范围变化 -13%·当前参与者 42

参与者计数42
0204060
热度走势
010020030010月19日04:0010月21日06:0010月23日09:0010月25日11:00

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会（CBA）www.cba-usa.org